# Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

> **NCT00400816** · PHASE2 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 29 (actual)

## Conditions studied

- Central Nervous System Tumors
- Brain Tumor

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00400816
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-01-17
- **Final completion:** 2016-01-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400816, "Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00400816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*